A 4250

Drug Profile

A 4250

Alternative Names: A-4250

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Albireo AB
  • Developer Albireo Inc; Albireo Pharma
  • Class Antipruritics
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis; Intrahepatic cholestasis; Alagille syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intrahepatic cholestasis; Primary biliary cirrhosis; Pruritus
  • Phase I Alagille syndrome

Most Recent Events

  • 14 Mar 2017 Preliminary efficacy data from a phase II trial in Pruritus released by Albireo
  • 08 Mar 2017 Albireo completes a phase I trial in Pruritus, Primary biliary cirrhosis, Intrahepatic cholestasis and Alagille syndrome (In volunteers) in United Kingdom (NCT03082937)
  • 31 Jan 2017 Phase-I clinical trials in Alagille syndrome (In volunteers) in United Kingdom (PO) (NCT03082937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top